Ozempic's biggest side effect: Turning Denmark into a 'pharmastate'?

Economics, Supply & Competition

• Demand for Ozempic/Wegovy is seen as supply‑constrained; many claim “everyone” wants it, but starter doses are hard to get and pharmacies worry about ongoing supply.
• Some argue scarcity is driven by injector‑pen manufacturing, not the active ingredient, and suspect intentional scarcity since vials plus standard syringes are possible.
• Debate over pricing: some see current price as profit‑maximizing under limited supply; others note prices should fall as capacity and competition grow.
• Patents are expected to expire within a decade; commenters expect a “massive” wave of generics and rival GLP‑1 drugs that should push prices down.
• Many biotechs reportedly have GLP‑1 or multi‑agonist (dual/triple) obesity drugs in the pipeline, some aiming for oral forms and greater efficacy.

Access, Compounding & Counterfeits

• Some users obtain semaglutide from compounding pharmacies via telehealth for ~$200–400/month, typically in multi‑dose vials.
• There is concern about variable quality (e.g., “salt semaglutide”), dosing errors, and reliance on short‑supply exemptions.
• Reports of easy OTC access in places like Mexico are met with skepticism due to counterfeit risks and inconsistent quality in tourist‑focused pharmacies.

Alternatives: Stimulants vs GLP‑1

• Several compare GLP‑1 drugs to Adderall/phentermine for weight loss.
• Stimulants suppress appetite and improve ADHD symptoms for some, but many note tolerance, intense side effects, high addiction/psychosis and cardiovascular risk, and historical withdrawal of amphetamine weight‑loss drugs.
• GLP‑1 agonists are seen as more appropriate for obesity because of better risk/benefit in trials and lack of controlled‑substance issues.

Health Effects, Use Cases & Long‑Term Role

• People at healthy BMI ask about benefits; speculative mentions include possible neuroprotective effects and ADHD help, but evidence is described as early or n=1.
• Many emphasize GLP‑1s change hunger/satiety and relationship with food rather than being a “fire‑and‑forget” fix.
• One view: Ozempic is not a true long‑term solution; diet, nutrition education, and monitoring are.

Obesity, Willpower & Environment

• Strong divide: some frame obesity largely as lack of willpower and gluttony; others argue this is judgmental and ignores biology, environment, and ultra‑processed food engineering.
• Cited evidence/claims include links between obesity and geography/altitude, pollution, cheap energy‑dense foods, and food deserts; critics counter with examples of affordable healthy diets, especially in Europe.
• Debate over whether drugs like Ozempic are a “band‑aid” versus legitimate therapy that effectively raises “willpower” for those who lack it.

Denmark, Novo Nordisk & “Pharmastate” Concerns

• Novo Nordisk is portrayed as extraordinarily large and central to Denmark’s economy, paying huge domestic taxes and being foundation‑owned, which may reduce tax‑avoidance incentives.
• Some see media claims that the company “saved Denmark from recession” as overstated and note that labor is fungible; in a different sector it might have produced equal or greater value.
• Others point out the firm’s dominance makes growing alternative Danish champions difficult, raising concerns about economic concentration.